Reviewed listing: NASDAQ:AUPH · Analysis dated Oct 31, 2026
How does the company make money?
Aurinia sells LUPKYNIS, a medication for adults with lupus-related kidney disease, and also earns revenue from collaborations and licenses. Most sales come from LUPKYNIS.
What supports the business?
LUPKYNIS sales rose in the third quarter from 70.6 to 79.4 million USD compared with the same quarter a year earlier. Operating profit also increased, although net income was almost unchanged.
What could improve?
Aurinia raised its 2026 revenue forecast from 315–325 to 325–330 million USD after growth in LUPKYNIS sales. Continued sales could support earnings, but that is not certain.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
At 16.65 USD, the stock appears reasonable, but not clearly cheap. Its calculated market value is about 2.23 billion USD, compared with a 2026 revenue forecast of 325 to 330 million USD. Revenue alone does not show whether the price is reasonable; earnings and dependence on the main drug also need to be considered.
What is the main risk?
Aurinia generates most of its revenue from LUPKYNIS, so competition or patent problems could significantly hurt the business. Research costs also rose in the third quarter from 8.4 to 16.6 million USD.
What is the overall assessment?
Aurinia is growing and holds substantial cash and short-term investments. The specified price appears reasonable, but higher research costs, little growth in the latest net income, and dependence on LUPKYNIS mean the balance of business quality, price, and risk is not yet convincing.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign in